Best use of targeted agents for the treatment of advanced renal cell carcinoma

European Journal of Oncology Pharmacy

Volumn 3, Issue 1, 2009, Pages 8-12

  Négrier, Sylvie ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; BEVACIZUMAB; KETOCONAZOLE; LEVOTHYROXINE; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; METASTASIS; MOUTH ULCER; PATIENT EDUCATION; PATIENT MONITORING; PROGNOSIS; REVIEW; SKIN TOXICITY; STOMATITIS; TASTE DISORDER; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 77953468062     PISSN: 17833914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Motzer RJ, Bander NH, Nanus DM, et al. Renal-cell carcinoma. N Engl J Med. 1996;335:865-875
2. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581-592
3. Ljungberg B, Hanbury D, Kuczyk M, et al. Renal cell carcinoma guideline. Eur Urol. 2007;51:1502-1510
4. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005;CD001425.
5. Pfizer Inc. SUTENT (sunitinib) SPC, January 2008.
6. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med. 2007;356:115-124 (Pubitemid 46089672)
7. Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma. Oral (abstract 5024). Presented at the 44th ASCO Annual meeting, Chicago, USA, May 30-June 3, 2008.
8. Négrier S, Figlin RA, Hutson TE, et al. Overall survival with sunitinib versus interferon alpha as first-line treatment of metastatic renal cell carcinoma. Poster (abstract 588). Presented at the 33rd ECMO Congress, Stockholm, Sweden, 12-16 September 2008.
9. Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol. 2007;178:1883-1887 (Pubitemid 47538608)
10. Hariharan S, Szczylik C, Porta C, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases: data from an expanded access trial. Poster (abstract 5094). Presented at the 44th ASCO Annual meeting, Chicago, USA, May 30-June 3, 2008.
11. Bayer Healthcare AG. Nexavar (sorafenib) SPC, April 2008.
12. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134 (Pubitemid 46089673)
13. Bukowski R, Szczylik C, Stadler W, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. Oral (abstract 5023). Presented at the 43rd ASCO Annual meeting, Chicago, USA, June 1-5, 2007.
14. Escudier B, Szczylik C, Demkow T, et al. First-line phase II study of sorafenib versus interferon-a2a in patients with unresectable and/or metastatic renal cell carcinoma. Presented at the 5th International Symposium on Targeted Anticancer Therapies, Amsterdam, The Netherlands, 8-10 March 2007.
15. Ryan CW, Bukowski RM, Figlin R, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: long-term outcomes in first-line patients. J Clin Oncol. 2007;25:5096.
16. Hiles JJ, Kolesar JM. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health-Syst Pharm. 2008;65:123-131
17. Wyeth Pharmaceuticals Inc. Torisel (temsirolimus) SPC, November 2007.
18. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281 (Pubitemid 46849157)
19. Roche Products Ltd. Avastin (bevacizumab) SPC, August 2008.
20. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, doubleblind phase III trial. Lancet. 2007;370:2103-2111 (Pubitemid 350296300)
21. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26:5422-5428
22. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer v.1.2009. National Comprehensive Cancer Network: http://www.nccn.org/professionals/physician-gls/PDF/ki dney.pdf
23. Porta C, Szczylik C, Bracarda S, et al. Short- and longterm safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma. Poster (abstract 5114). Poster (abstract 5094). Presented at the 44th ASCO Annual meeting, Chicago, USA, May 30-June 3, 2008.
24. Négrier S, Ravaud A. Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. Eur J Cancer Suppl. 2007;5(7):12-19 (Pubitemid 350017071)